408 related articles for article (PubMed ID: 36279982)
1. Drug conjugate-based anticancer therapy - Current status and perspectives.
Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
[TBL] [Abstract][Full Text] [Related]
2. Peptide Drug Conjugates and Their Role in Cancer Therapy.
Heh E; Allen J; Ramirez F; Lovasz D; Fernandez L; Hogg T; Riva H; Holland N; Chacon J
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614268
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
4. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy.
Lindberg J; Nilvebrant J; Nygren PÅ; Lehmann F
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641586
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer.
Xu J; Li X; Du Y
Adv Biol (Weinh); 2022 Mar; 6(3):e2101065. PubMed ID: 35122418
[TBL] [Abstract][Full Text] [Related]
8. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates and Tissue-Agnostic Drug Development: An Update.
Dias E Silva D; Andriatte GM; Pestana RC
Cancer J; 2022 Nov-Dec 01; 28(6):462-468. PubMed ID: 36383909
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates: Principles and opportunities.
Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
[TBL] [Abstract][Full Text] [Related]
13. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.
Tong JTW; Harris PWR; Brimble MA; Kavianinia I
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641391
[TBL] [Abstract][Full Text] [Related]
14. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
15. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy.
Alas M; Saghaeidehkordi A; Kaur K
J Med Chem; 2021 Jan; 64(1):216-232. PubMed ID: 33382619
[TBL] [Abstract][Full Text] [Related]
16. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
17. Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.
Porębska N; Ciura K; Chorążewska A; Zakrzewska M; Otlewski J; Opaliński Ł
Biotechnol Adv; 2023 Oct; 67():108213. PubMed ID: 37453463
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
[TBL] [Abstract][Full Text] [Related]
19. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
20. Site-specific antibody drug conjugates for cancer therapy.
Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]